AIV Logo AIV Assistant

Loading...

 Logo Soleno Therapeutics, Inc. - SLNO 83.59 USD

EPS
-2.79
P/B
7.45
ROE
-91.11
Beta
-1.44
Target Price
74.29 USD

83.590 USD

83.590 USD

Daily: +0.00%
Key Metrics

EPS: -2.79

Book Value: 6.45

Price to Book: 7.45

Debt/Equity: 1.14

% Insiders: 3.047%

Estimates

Forward P/E: -21.17

Forward EPS: -2.27

Target Mean Price: 74.29

 Logo About Soleno Therapeutics, Inc. - (SLNO)

Country: United States

Sector: Health Care

Website: http://soleno.life

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Exchange Ticker
NMS (United States) SLNO

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Oct. 6, 2017 0.20
Aug. 26, 2022 0.07
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion